GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » Quick Ratio
中文

Capricor Therapeutics (Capricor Therapeutics) Quick Ratio

: 1.63 (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Capricor Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 1.63.

Capricor Therapeutics has a quick ratio of 1.63. It generally indicates good short-term financial strength.

The historical rank and industry rank for Capricor Therapeutics's Quick Ratio or its related term are showing as below:

CAPR' s Quick Ratio Range Over the Past 10 Years
Min: 1.63   Med: 5.23   Max: 11.74
Current: 1.63

During the past 13 years, Capricor Therapeutics's highest Quick Ratio was 11.74. The lowest was 1.63. And the median was 5.23.

CAPR's Quick Ratio is ranked worse than
69.8% of 1553 companies
in the Biotechnology industry
Industry Median: 3.56 vs CAPR: 1.63

Capricor Therapeutics Quick Ratio Historical Data

The historical data trend for Capricor Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.74 11.34 8.82 1.82 1.63

Capricor Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 1.25 1.11 0.90 1.63

Competitive Comparison

For the Biotechnology subindustry, Capricor Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Quick Ratio falls into.



Capricor Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Capricor Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(50.855-0)/31.27
=1.63

Capricor Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(50.855-0)/31.27
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Capricor Therapeutics  (NAS:CAPR) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Capricor Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics (Capricor Therapeutics) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Executives
David B Musket director C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat officer: CHIEF BUSINESS OFFICER 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar director C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban director, officer: CHIEF EXECUTIVE OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr director C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney officer: EVP, GENERAL COUNSEL C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann officer: CHIEF FINANCIAL OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo director C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center 10 percent owner 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A. 10 percent owner 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022

Capricor Therapeutics (Capricor Therapeutics) Headlines

From GuruFocus

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

By GuruFocusNews GuruFocusNews 07-04-2022